Spherix Enters Into Non-Binding Letter Of Intent with Privacy Messaging Pioneer DatChat

NEW YORK, Aug. 9, 2016 -- Spherix Incorporated (SPEX) –a company committed to the fostering of technology and the monetization of intellectual property, today announced that it has entered into a non-binding letter of intent ("LOI") to invest in DatChat Inc. – a pioneer in the secure (privacy) messaging industry – in exchange for an equity security interest in DatChat. DatChat's patent-pending encryption technology allows users to secure their messages sent between mobile devices. Earlier this year, DatChat announced that its technology offers an unprecedented level of privacy control for both individual and group messages. According to DatChat, its app is the first privacy messaging app that provides the option to dictate how long sent messages are accessible on the recipient's phone and is the first to offer an option that will erase both sides of a conversation on both the sender and recipient's devices, even after the information is transmitted to another user. Currently, the DatChat app is available in theiTunes® store.

Published: 09 August 2016

Written by Editor

Nasdaq Up on News Project Update

Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001

SOLANA BEACH, Calif., July 26, 2016 -- Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the US Food and Drug Administration (FDA) has conditionally accepted the proprietary brand name, “Gimoti,” for the Company’s product candidate, EVK-001 (metoclopramide nasal spray). A request for proprietary name review for Gimoti will be included if and when Evoke submits a New Drug Application (NDA) for the product candidate.

The name Gimoti (pronounced “jye-MOH-tee”) was developed in compliance with the FDA’s Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names (issued in February 2010). The development program, which included research with physicians and pharmacists, as well as an international name assessment, confirmed Gimoti is a proprietary name with strong marketing potential that is also consistent with the FDA’s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use.

Published: 28 July 2016

Written by Editor

Nasdaq FDA HC Decision Up on News

Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam

IV Meloxicam Achieves Primary Endpoint in First of Two Pivotal Trials

Fifteen of Nineteen Secondary Endpoints Also Met

Management to Host Conference Call and Webcast Today at 5:00 PM ET

MALVERN, Pa., July 26, 2016 -- Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain, today announced positive results from its Phase III clinical trial evaluating intravenous (IV) meloxicam (N1539) for the treatment of acute postoperative pain in patients following bunionectomy surgery. In the trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 48 hours (SPID48) compared to placebo.

Published: 27 July 2016

Written by Editor

Nasdaq Up on News Project Update

Critical Elements (TSXV: CRE) and Ionic to Explore Valiquette and Amiral Lithium Properties in Quebec

MONTREAL, QUEBEC--(Jul 18, 2016) - Critical Elements Corporation ("Critical Elements" or the "Company") (TSX VENTURE:CRE)(CRECF)(F12.F) and Ionic Power Corp. ("Ionic") are pleased to announce that Critical Elements and Ionic have entered into an option agreement ("Agreement") that gives Ionic the right to acquire up to a 75% interest in the Valiquette and Amiral projects, located south-west to the Nemaska Lithium Whabouchi Deposit.

"The Valiquette and Amiral projects represent a great opportunity for Ionic, Critical Elements and the shareholders of both entities."

"This option agreement with Ionic will allow the Valiquette and Amiral properties to be explored in detail for a Lithium Pegmatite discovery. Critical Elements is currently focused on the development of its Rose lithium-tantalum project. With Ionic farming into the Valiquette and Amiral projects, shareholders of both companies will be able to benefit from successful exploration of a highly prospective project," stated Jean-Sébastien Lavallée, President and CEO, Critical Elements.

Published: 18 July 2016

Written by Editor

Up on News Project Update TSXV

Helius Medical Announces Results from a Case Series of Subjects with Advanced MS

NEWTOWN, Pa.-- Helius Medical Technologies, Inc. (TSX: HSM, HSM.S, OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce the results of a case series of individuals with advanced symptoms of Multiple Sclerosis (MS) treated with PoNS™ Therapy.

This study was performed at TCNL1, University of Wisconsin, Madison and the data was presented at the 2016, Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Six subjects with advanced MS (Expanded Disability Status Scale (EDSS)2 scores ranging from 6.5 to 7.5) were enrolled in a six-month pilot study. Subjects were trained in PoNS™ Therapy which combines use of the prototype PoNS™ device with physical training in balance, gait, movement and postural stability. Results demonstrated improvements in physical, cognitive and quality of life parameters. The demanding training regimen also resulted in significant real life improvements such as re-adopting a walker for community mobility, decreased fatigue, increased independence with daily activities, overcoming physical obstacles at home and increased community access.

Published: 21 June 2016

Written by Editor

TSX Up on News Project Update

Page 6 of 25

Spherix Incorporated ( SPEX )

Spherix Enters Into Non-Binding Letter Of Intent with Privacy Messaging Pioneer DatChat

Evoke Pharma Inc ( EVOK )

Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001

Recro Pharma Inc ( REPH )

Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam

Critical Elements Corporation ( CRE )

Critical Elements (TSXV: CRE) and Ionic to Explore Valiquette and Amiral Lithium Properties in Quebec

Helius Medical Technologies Inc ( HSM )

Helius Medical Announces Results from a Case Series of Subjects with Advanced MS